Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gene-editing

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

regeneron headquarters

Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration

The companies will develop CRISPR-based therapies for neurological and muscular diseases

regeneron headquarters

Regeneron’s Veopoz granted FDA approval for ultra-rare immune disease

Fewer than ten patients in the US have been diagnosed with CHAPLE disease

- PMLiVE

Moderna and Life Edit partner to accelerate gene editing therapies

The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine

The results were published in a peer-reviewed paper in Nature

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Impetus Digital

- PMLiVE

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

Impetus Digital

Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients

Sandra Graham-Mason, Director of Marketing at Regeneron Pharmaceuticals discusses a variety of topics, from the impact of COVID-19 on the way that Pharma teams interact with internal stakeholders and KOLs to...

Impetus Digital

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links